1 week Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCCZacks
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
X